CD274 and lung carcinoma: Strikingly, NAD replenishment through exogenous NMN supplementation sensitized anti-PD-(L)1 therapy-resistant (PD-L1 low) tumors to immunotherapy in mice models representing immunotherapy-tolerant lung cancer, pancreatic cancer, and hepatic cancer [201].